abs249.txt	cabozantinib	is	a	multikinase	inhibitor	approved	for	the	treatment	of	metastaticmedullary	thyroid	cancer	and	advanced	renal	cell	carcinoma	(rcc)	in	patients	whohave	received	prior	anti-angiogenic	therapy		while	associations	between	serumcreatine	kinase	(ck)	elevations	other	tyrosine	inhibitors	used	thetreatment	solid	malignancies	have	been	previously	reported	we	report	caseof	cabozantinib-associated	ck	elevation	that	was	associated	with	musculoskeletalcomplaints	by	an	rcc	patient	nine	days	following	initiation	thepatient	muscle	cramps	serum	had	increased	from	levels	12	monthsearlier	were	within	normal	limits	to	grade	1	244	units/l	despite	dose	reduction	her	continued	rise	over	next	2	months	leading	peak	914	due	this	3	cabozantinibwas	permanently	discontinued	subsequently	returned	1elevation	one	week	then	baseline	weeks	temporalrelationship	drug	exposure	increase	strongly	suggests	causality	authors'	knowledge	first	case	elevationattributed	but	cabozantinib-induced	could	beunder-reported	providers	should	monitor	musculoskeletal	complaintsduring
